Anifrolumab (Saphnelo): blocking type I interferon in lupus
A 2-minute narrated animation of type I interferon signaling in SLE and IFNAR1 blockade by anifrolumab (Saphnelo). Open professional education.
Educational Video · Professionals · EN
Olga Goodman, MD · Rheumatology in Perspective
Published · Updated October 3, 2026
Clinically reviewed: 2026-10-03
Evidence checked through: 2026-10-03
Where anifrolumab interrupts the signal
In systemic lupus erythematosus (SLE), type I interferons can sustain a cycle of immune activation. The animation follows immune-complex sensing, interferon release and signaling through IFNAR1/IFNAR2, JAK1/TYK2 and STAT proteins to interferon-stimulated genes.
Anifrolumab (Saphnelo) binds IFNAR1, a subunit of the type I interferon receptor, and inhibits this signaling pathway. Its target is the receptor; it does not directly inhibit JAK or TYK2 enzymes. The simplified sequence helps locate the intervention within the immune network, while individual clinical responses vary.
Anifrolumab is used with standard therapy for adults with moderate-to-severe SLE. Current U.S. labeling does not recommend its use in severe active lupus nephritis or severe active CNS lupus. This mechanism overview is not a treatment-selection or dosing guide.